Skip to content
Review Open access

The Tumor-Bed Boost Irradiation in Early-Stage Breast Cancer 30 Years After the Landmark Trials: What Is New?

Sep 2026 · Journal of Personalized Medicine · Vol 16, pp. 473 · 0 citations · 71 references
Medicine

TL;DR

Current evidence supports a more individualized approach to boost prescription based on recurrence risk, patient age, tumor biology, margin status, treatment techniques, and patient preference, and unresolved clinical issues still remain about the management of positive or close margins.

Abstract

Breast-conserving surgery followed by adjuvant whole-breast irradiation (WBI) remains the standard of care for patients with early-stage breast cancer. In this setting, irradiation of the tumor bed with an additional boost dose has historically been used to reduce the risk of ipsilateral breast tumor recurrence (IBTR). Major randomized trials established that boost irradiation improved local control, particularly in younger patients, but did not confer a consistent overall survival (OS) benefit and was associated with increased late toxicity, like fibrosis, and poorer cosmetic outcomes as well. More recent evidence, including systematic reviews and contemporary consensus recommendations, suggests that boost irradiation may be safely omitted in selected low-risk patients, especially when the estimated absolute reduction in 10-year local recurrence is less than 3%. At the same time, the routine use of boost irradiation has been challenged by modern systemic therapy treatments questioning if boost could be really omitted in this set. Further advances in radiation techniques are redefining the scheduling and timing of boost administration, shifting from a conventional fractionation to hypofractionation and from the sequential (SEB) to simultaneous delivery with simultaneous integrated boost (SIB). In light of increasingly minimally invasive surgery and a de-escalation RT policy, unresolved clinical issues still remain about the management of positive or close margins and the role of boost irradiation in ductal carcinoma in situ. This narrative review summarizes the biological rationale, historical trial evidence, and recent literature addressing these evolving scenarios. Current evidence supports a more individualized approach to boost prescription based on recurrence risk, patient age, tumor biology, margin status, treatment techniques (surgery and radiotherapy), and patient preference.

Read PDF

Similar papers

Open access Sep 2026

Intraoperative or postoperative radiotherapy boost in high-risk breast cancer: a matched-pair analysis

The optimal boost technique following breast-conserving surgery for patients with high-risk early breast cancer remains controversial. This study compared oncologic outcomes following an intraoperative radiotherapy (IORT) boost using low-energy X‑rays with those of a conventional external beam radiotherapy (EBRT) boost...

G. R. Sarria, C. Dejonckheere, J. Fernandez et al. · 0 citations
Open access Sep 2026

Five-year outcomes of partial breast proton beam therapy without lumpectomy for early-stage breast cancer: an interventional prospective study

Preliminary clinical observations suggest that PB-PBT without lumpectomy achieves results within specific criteria and that it could be an option for breast cancer treatment using radiation therapy alone.

E. Ogo, T. Arimura, T. Ogino et al. · 0 citations
Review Open access Oct 2026

Feasibility and Outcomes of Concomitant Boost in Prone Hypofractionated Whole-Breast Irradiation Using 3D-Conformal Radiotherapy.

BACKGROUND Adjuvant radiation after breast-conserving surgery (BCS) reduces recurrence and improves survival in early breast cancer. While hypofractionated whole-breast irradiation (WBI) is standard, use of a concomitant boost (CB) remains limited. We report outcomes using moderately hypofractionated WBI with CB (HFRT-...

Pavnesh Kumar, T. Jitwatcharakomol, J. Schoenhals et al. · 0 citations
Review Oct 2026

Safety and early outcomes of external beam radiation therapy with low dose brachytherapy boost in patients with prostate cancer: A single institution experience.

Findings support this approach for appropriately selected patients in routine clinical care for intermediate- and high-risk prostate cancer, as contemporary real-world evidence remains limited.

Z. El Kouzi, M. Rooney, Adam B. Samman et al. · 0 citations
Review Aug 2026

Postoperative radiotherapy after radical cystectomy for muscle-invasive bladder cancer: Patient selection, target delineation and contemporary evidence.

Following radical cystectomy, muscle-invasive bladder cancer remains associated with a substantial risk of locoregional recurrence, particularly in patients with pT3-4 disease, nodal involvement, positive surgical margins, or limited pelvic lymph node dissection. Historically, adjuvant radiotherapy reduced pelvic recur...

Constance Huck, Claire Zobouyan, G. Pignot et al. · 0 citations
2024

What about radiotherapy for rectal cancer?

Rectal cancer represents one of the most difficult oncological challenges due to its high risk of recurrence and multiple treatment complications. Recent decades have witnessed significant advances in the treatment of this malignancy, mainly due to the introduction of Total Mesorectal Excision and the use of perioperat...

Z. Lorenc, Jakub Wantulok, M. Święch et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.